☆ Ajouter favori
Fiche traitement

Valproate

M.D. Anderson Cancer Center • Épilepsie

Suivi actif Phase 2/3

Résumé

Valproate est développé par M.D. Anderson Cancer Center. Le traitement est actuellement en Phase 2/3. Il est associé à Épilepsie. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.

À vérifier

À vérifier
Phase 2/3
M.D. Anderson Cancer Center
United States
Migraine is one of the three most disabling diseases worldwide. Constituted by recurrent episodes of headache, characterized by unilateral location, throbbing character, moderate or severe intensity, worsening with physical activity, and association with nausea or photophobia and/or phonophobia. There are two types of drug treatment: abortifacient and prophylactic. The American Academy of Neurology classifies sodium valproate as level A; however, some patients do not obtain a satisfactory response rate and/or have adverse effects. Therefore, the search for new pharmacological treatments continues. In 2015, a double-blind, randomized clinical trial with a placebo was carried out to assess Memantine's efficacy in the prophylactic treatment of migraine without aura, which reported a reduction of 2.3 migraine attacks per month compared to the placebo group. Memantine could be a new effective treatment alternative, which is why we will compare the efficacy of Memantine against sodium valproate as a prophylactic migraine treatment. Main objective: To compare the efficacy of Memantine at a rate of 20mg divided into two doses a day against sodium valproate (VPA) at a rate of 1000mg divided into two doses a day prophylactic treatment of migraine for three months. Study design: a prospective controlled, randomized, double-blind clinical trial. Inclusion criteria: Men and women aged 18 to 65 years with a diagnosis at least one year before the study must present at least 2 to 8 migraine attacks per month and less than 15 days with headache per month, which should not be receiving prophylactic treatment for migraine and sign an informed consent Sample size calculation and statistical analysis: It is calculated using the normal distribution model, where the recommended sample size is 196 participants. Since a pilot study will be conducted, 10% of the sample size will be taken to make it representative, a sample size of 20 participants is decided for each group.
2026-11-13

Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique

Phase 2/3
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé

Objectif scientifique de l’étude

classification automatique vérifiable
À vérifier Confiance automatique : 0%

Description affichée depuis l’essai compatible NCT04698525, afin d’éviter le mélange entre plusieurs indications d’une même molécule.

Contrôle de cohérence : 85/100

L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.

Transparence et qualité de la fiche

données vérifiables
ClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-11-13
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source Donnée normalisée automatiquement Interprétation algorithmique

Classification scientifique multi-axes

ne pas confondre statut et résultat
État de l’étudeTerminée
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable

Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.

Indicateurs factuels

sans score subjectif
Phase enregistréePhase 2/3
Études associées2
Publications associées14
Statut consolidéSuivi actif

Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.

Historique factuel de la molécule

22 événement(s) daté(s)

Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.

DateÉvénementSource
2019-02-15Début de l’étudeNCT04698525Registre d’essai clinique
2020-01-15Fin de l’étude prévue / enregistréeNCT04698525Registre d’essai clinique
2022-10-18Début de l’étudeNCT05722951Registre d’essai clinique
2024-06-20Fin de l’étude prévue / enregistréeNCT05722951Registre d’essai clinique
2026-07-08PublicationAnti-seizure medication in Germany over 25 years: trends in prices and prescription patterns from national data from 2000 to 2024.Epilepsy & behavior : E&B
2026-07-12Création de l’enregistrementNCT05722951Registre d’essai clinique
2026-07-12PublicationTodd's Paralysis Simulating Acute Ischemic Stroke: A Case Report.Cureus
2026-07-13Dernière mise à jour du registreNCT05722951Registre d’essai clinique
2026-07-14PublicationPharmacist-led management of suspected drug-provoked seizures and sequential antiseizure medication adverse reactions: a case report.Frontiers in pharmacology
2026-07-14PublicationA Novel RORA Hinge-Region Variant in Adult IDDECA With Cerebellar Atrophy and Marked Response to Valproate.European journal of neurology
2026-07-15PublicationHigh Volume Hemofiltration : what are the last indications in 2026 - a narrative review.Blood purification
2026-07-18PublicationAntiseizure medication dosing and monitoring in the intensive care unit: a practical narrative review.Intensive care medicine
2026-08-08Publication2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.Headache
2026-08-08PublicationA Case of Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) With Coagulopathy and Altered Consciousness.Acute medicine & surgery
2026-08-16Création de l’enregistrementNCT04698525Registre d’essai clinique
2026-08-16PublicationProphylactic anti-seizure medication for post-traumatic seizures in Chinese PICUs: current practices and knowledge gaps.BMC neurology
2026-08-16PublicationA phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
.International journal of clinical pharmacology and therapeutics
2026-08-16PublicationSLC6A1-Related Neurodevelopmental Disorder: A Scoping Review of Clinical Features and Emerging Therapeutic Strategies.Pediatric neurology
2026-08-16PublicationSYNGAP1-related disorder: pathophysiology, epilepsy, cognitive and behavioral phenotypes, and precision therapeutic approaches.Epilepsy & behavior : E&B
2026-08-16PublicationInteractions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice.Neuropharmacology
2026-11-13Dernière mise à jour des donnéesValproateBiomedical Watch
2026-11-22PublicationInvestigating seizures in bariatric surgery patients: Pre- and postoperative perspectives: A systematic review.Obesity pillars

Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés

2 essai(s)
NCT Titre Phase Statut administratif Pays Sponsor
NCT04698525 Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. Phase 3 COMPLETED Mexico Universidad Autonoma de San Luis Potosí
NCT05722951 Metformin Efficacy and Safety in Epileptic Patients Phase 3 COMPLETED Egypt Tanta University

Publications liées

14 publication(s)

Publications liées

14 publication(s)
Titre PMID DOI Journal Date
Investigating seizures in bariatric surgery patients: Pre- and postoperative perspectives: A systematic review. Voir source 42799053 10.1016/j.obpill.2026.100326 Obesity pillars
Prophylactic anti-seizure medication for post-traumatic seizures in Chinese PICUs: current practices and knowledge gaps. Voir source 42260360 10.1186/s12883-026-04974-7 BMC neurology
A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
. Voir source 30336805 10.5414/CP203276 International journal of clinical pharmacology and therapeutics
SLC6A1-Related Neurodevelopmental Disorder: A Scoping Review of Clinical Features and Emerging Therapeutic Strategies. Voir source 42173049 10.1016/j.pediatrneurol.2026.04.014 Pediatric neurology
SYNGAP1-related disorder: pathophysiology, epilepsy, cognitive and behavioral phenotypes, and precision therapeutic approaches. Voir source 42161154 10.1016/j.yebeh.2026.111098 Epilepsy & behavior : E&B
Interactions between SSR504734, a selective glycine transporter type 1 inhibitor, and antiseizure drugs: pharmacodynamic and pharmacokinetic studies in mice. Voir source 42214459 10.1016/j.neuropharm.2026.111046 Neuropharmacology
2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. Voir source 41321235 10.1111/head.70016 Headache
A Case of Lamotrigine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) With Coagulopathy and Altered Consciousness. Voir source 42559111 10.1002/ams2.70156 Acute medicine & surgery
Antiseizure medication dosing and monitoring in the intensive care unit: a practical narrative review. Voir source 42455344 10.1007/s00134-026-08550-y Intensive care medicine
High Volume Hemofiltration : what are the last indications in 2026 - a narrative review. Voir source 42447139 10.1159/000553509 Blood purification
Pharmacist-led management of suspected drug-provoked seizures and sequential antiseizure medication adverse reactions: a case report. Voir source 42445248 10.3389/fphar.2026.1853932 Frontiers in pharmacology
A Novel RORA Hinge-Region Variant in Adult IDDECA With Cerebellar Atrophy and Marked Response to Valproate. Voir source 42438296 10.1111/ene.70699 European journal of neurology
Todd's Paralysis Simulating Acute Ischemic Stroke: A Case Report. Voir source 42437250 10.7759/cureus.110685 Cureus
Anti-seizure medication in Germany over 25 years: trends in prices and prescription patterns from national data from 2000 to 2024. Voir source 42398365 10.1016/j.yebeh.2026.111174 Epilepsy & behavior : E&B

Sources officielles

liens de recherche

Dernière mise à jour des données : 2026-11-13

Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.